New Delhi, Dec. 12 -- Pharmaceutical firm Corona Remedies, whose IPO garnered massive investor interest during its three-day bidding period, with subscription crossing over 144 times, is set to debut on the bourses on Monday, December 15.

Ahead of the listing, the shares are commanding a solid grey market premium (GMP). According to market sources, they are quoting at Rs.291 per share, and taking the shares' upper band issue price of Rs.1,062 and the current GMP into account, the estimated listing price of Corona Remedies comes to Rs.1,353 per share, which is 27.40% higher.

The grey market premium reflects the expected difference between an IPO's issue price and its anticipated listing price in the unofficial market. However, analysts c...